Abstract

Objectives: The aim of this study was to assess the effect of the pro-inflammatory interleukin (IL)-17A in deep venous thrombosis (DVT) resolution. Materials and Methods: A total of 45 DVT patients, 30 primary deep venous insufficiencies (DVI) patients, and 18 healthy volunteers were divided into three groups: (a) Control group, (b) DVT group, and (c) DVI group. The venous blood samples of the lower extremity with DVT were collected to evaluate the expression of IL-17A in plasma. Samples of superficial venous thrombus and superficial vein without thrombosis were collected to evaluate the expression of IL-17A in tissue. Male C57/BL mice DVT model was established and was randomly divided into five groups: (1) Control group, no treatment or surgical intervention; (2) Sham group, no treatment and sham operation; (3) DVT group, each mouse intravenous (iv) injected with phosphate-buffered saline (PBS); (4) IL-17A group, each mouse was iv injected with IL-17A; and (5) IL-17A-neutralizing antibody (NA) group, each mouse was iv injected with IL17A NA. Inferior vena cava (IVC) with thrombi were collected to measure their length and weight and analysis CD31(+) endothelial cells in thrombus of internal cerebral vein. Results: Western blot suggested that the expression of IL-17A in superficial vein with thrombosis was higher than superficial vein without thrombosis from human samples (P

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call